A Phase 3 interventional study of sildenafil citrate (UK-92,480) in Pulmonary Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 8 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 7th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is close to the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2007, is one of 3 in phase 3, and was the 5th registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1)
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's enrollment of 44 is close to the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
sildenafil citrate 20 mg TID
Drug: sildenafil citrate (UK-92,480)
sildenafil citrate (UK-92,480)
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:total distance walked during the 6-minute walk test.
Time frame: Baseline, Week 12
Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.
Time frame: Baseline, Week 12
Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline
Time frame: Baseline, Week 12
Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Cardiac output at Week 12 minus cardiac output at baseline
Time frame: Baseline, week 12
Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I
Change:6-minute walk distance at Week 8 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.
Time frame: Baseline, Week 8
Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.
Time frame: Baseline, Week 12
Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.
Time frame: Baseline, Week 12
Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.
Time frame: Baseline, Week 12
Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.
Time frame: Baseline, Week 12
Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3. Change:Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline.
Time frame: Baseline, Week 12
Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.
Time frame: Baseline, Week 12
Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Right atrial pressure at Week 12 minus right atrial pressure at baseline.
Time frame: Baseline, Week 12
Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Cardiac index at Week 12 minus cardiac index at baseline.
Time frame: Baseline, Week 12
Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Heart rate at Week 12 minus heart rate at baseline.
Time frame: Baseline, Week 12
Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.
Time frame: Baseline, Week 12
Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.
Time frame: Baseline, Week 12
Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.
Time frame: baseline, Week 12
Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.
Time frame: Baseline, Week 12
Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.
Time frame: Baseline, Week 12
Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.
Time frame: baseline, Week 12
Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I
Change:Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.
Time frame: Baseline, Week 12
Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
Time frame: Baseline, Week 12
Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I
Change:BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
Time frame: Baseline, Week 8, Week 12
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I
Change:Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline
Time frame: Baseline, Week 4, Week 8, Week 12
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.
Time frame: Baseline, Week 12
Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
Time frame: Baseline, Week 12
Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
Change:BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
Time frame: Baseline, Week 12
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II
Change:Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline
Time frame: Baseline, Week 12
Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320
The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
The Average Plasma Concentration (Css,av) of Sildenafil at Steady State
The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
The Average Plasma Trough Concentration (Ctrough) of Sildenafil
The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
The total number of participants with laboratory test abnormalities without regard to baseline abnormality.
Time frame: Baseline up to 1.3 years
Eight centers in Japan
| Milestone | Sildenafil: Participant Who Entered the Study From Part I | Sildenafil: Participants Who Entered the Study From Part II |
|---|---|---|
| Started | 21 | 23 |
| Completed | 17 | 21 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:total distance walked during the 6-minute walk test.
| meters | Sildenafil: Part I |
|---|---|
| Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I | 84.2 ± 74.9 |
Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -4.7 ± 8.2 |
Change:Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline
| dyne·second/centimeter^5 | Sildenafil:Part I |
|---|---|
| Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I | -246.49 ± 301.17 |
Change:6-minute walk distance at Week 8 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.
| meters | Sildenafil:Part I |
|---|---|
| Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I | 87.5 ± 75.3 |
Change:Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -3.4 ± 13.4 |
Change:Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -3.2 ± 8.3 |
Change:Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.7 ± 16.5 |
Change:Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -3.1 ± 9.0 |
Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3. Change:Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -0.9 ± 12.9 |
Change:Cardiac output at Week 12 minus cardiac output at baseline
| liter/minute | Sildenafil:Part I |
|---|---|
| Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.556 ± 1.000 |
Change:Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.68 ± 3.14 |
Change:Right atrial pressure at Week 12 minus right atrial pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -0.3 ± 4.4 |
Change:Cardiac index at Week 12 minus cardiac index at baseline.
| liter/minute/meter^2 | Sildenafil:Part I |
|---|---|
| Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.32 ± 0.62 |
Change:Heart rate at Week 12 minus heart rate at baseline.
| beats/minute | Sildenafil:Part I |
|---|---|
| Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I | -4.14 ± 7.45 |
Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.
| dyne*second/centimeter^5/meter^2 | Sildenafil:Part I |
|---|---|
| Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I | -382.00 ± 491.80 |
Change:Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.
| dyne*second/centimeter^5 | Sildenafil:Part I |
|---|---|
| Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I | -265.77 ± 785.52 |
Change:Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.
| dyne*second/centimeter^5/meter^2 | Sildenafil:Part I |
|---|---|
| Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I | -409.89 ± 1271.30 |
Change:Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.
| percent saturation | Sildenafil:Part I |
|---|---|
| Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I | 2.91 ± 9.05 |
Change:Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.
| percent saturation | Sildenafil:Part I |
|---|---|
| Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.440 ± 5.437 |
Change:Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I | -2.02 ± 11.17 |
Change:Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.
| mmHg | Sildenafil:Part I |
|---|---|
| Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I | 0.57 ± 4.35 |
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
| participants | Sildenafil:Part I , Functional Class at Baseline: I | Sildenafil:Part I, Functional Class at Baseline: II | Sildenafil, Part I, Functional Class at Baseline: III | Sildenafil, Part I, Functional Class at Baseline:IV |
|---|---|---|---|---|
| Functional class at Week 12:I | — | 0 | 1 | — |
| Functional class at Week 12:II | — | 6 | 5 | — |
| Functional class at Week 12:III | — | 1 | 7 | — |
| Functional class at Week 12:IV | — | 0 | 0 | — |
Change:BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
| scores on a scale | Sildenafil:Part I |
|---|---|
| Week 8 (n=19, 0) | -0.84 ± 1.89 |
| Week 12 (n=20, 6) | -0.95 ± 1.94 |
Change:Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline
| picograms/milliliter | Sildenafil:Part I |
|---|---|
| Week 4 (n=20, 0) | -78.00 ± 166.41 |
| Week 8 (n=19, 0) | -88.25 ± 178.39 |
| Week 12 (n=20, 7) | -61.82 ± 209.96 |
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test.
| meters | Sildenafil:Part II |
|---|---|
| Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II | -23.5 ± 34.1 |
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12. The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
| participants | Sildenafil:Part II, Functional Class at Baseline: I | Sildenafil:Part II, Functional Class at Baseline: II | Sildenafil: Part II, Functional Class at Baseline: III | Sildenafil: Part II, Functional Class at Baseline: IV |
|---|---|---|---|---|
| Functional class at Week 12: I | 1 | 0 | — | — |
| Functional class at Week 12: II | 0 | 5 | — | — |
| Functional class at Week 12: III | 0 | 1 | — | — |
| Functional class at Week 12: IV | 0 | 0 | — | — |
Change:BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline. BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum). The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
| scores on a scale | Sildenafil: Part II |
|---|---|
| Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II | 0.33 ± 1.21 |
Change:Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline
| picograms/milliliter | Sildenafil:Part II |
|---|---|
| Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II | 15.91 ± 55.94 |
Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant
| nanograms/milliliter | Sildenafil:Pharmacokinetic Analysis Participant |
|---|---|
| Sildenafil | 164.88 ± 74.78 |
| Sildenafil's Metabolite, UK-103,320 | 87.27 ± 30.67 |
Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.
| hours | Sildenafil:Pharmacokinetic Analysis Participant |
|---|---|
| Sildenafil | 1.102 ± 0.499 |
| Sildenafil's Metabolite, UK-103,320 | 1.611 ± 1.024 |
The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule
| nanogram*hour/milliliter | Sildenafil:Pharmacokinetic Analysis Participant |
|---|---|
| Sildenafil | 545.14 ± 294.88 |
| Sildenafil's Metabolite, UK-103,320 | 365.85 ± 186.55 |
The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).
| nanograms/milliliter | Sildenafil:Pharmacokinetic Analysis Participant |
|---|---|
| The Average Plasma Concentration (Css,av) of Sildenafil at Steady State | 68.14 ± 36.86 |
The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.
| nanograms/milliliter | Sildenafil:Pharmacokinetic Analysis Participant |
|---|---|
| The Average Plasma Trough Concentration (Ctrough) of Sildenafil | 19.608 ± 12.438 |
The total number of participants with laboratory test abnormalities without regard to baseline abnormality.
| participants | Sildenafil: Part I and Part II |
|---|---|
| Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) | 35 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil: Part I and Part II | — | 7/44 (15.9%) | 42/44 (95.5%) |
| Event | Sildenafil: Part I and Part II |
|---|---|
| Cardiac failureCardiac disorders | 2/44 |
| AnorexiaMetabolism and nutrition disorders | 2/44 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/44 |
| CataractEye disorders | 1/44 |
| NauseaGastrointestinal disorders | 1/44 |
| NasopharyngitisInfections and infestations | 1/44 |
| PneumoniaInfections and infestations | 1/44 |
| Platelet count decreasedInvestigations | 1/44 |
| Scleroderma renal crisisRenal and urinary disorders | 1/44 |
| Event | Sildenafil: Part I and Part II |
|---|---|
| NasopharyngitisInfections and infestations | 17/44 |
| HeadacheNervous system disorders | 11/44 |
| FlushingVascular disorders | 10/44 |
| PyrexiaGeneral disorders | 5/44 |
| DiarrhoeaGastrointestinal disorders | 4/44 |
| FallInjury, poisoning and procedural complications | 4/44 |
| DizzinessNervous system disorders | 4/44 |
| Oedema peripheralGeneral disorders | 3/44 |
| Platelet count decreasedInvestigations | 3/44 |
| Back painMusculoskeletal and connective tissue disorders | 3/44 |
| Age, Categorical(Participants) | Sildenafil: Participant Who Entered the Study From Part I | Sildenafil: Participants Who Entered the Study From Part II | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 19 | 20 | 39 |
| >=65 years | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | Sildenafil: Participant Who Entered the Study From Part I | Sildenafil: Participants Who Entered the Study From Part II | Total |
|---|---|---|---|
| Female | 17 | 21 | 38 |
| Male | 4 | 2 | 6 |
| Region of Enrollment(participants) | Sildenafil: Participant Who Entered the Study From Part I | Sildenafil: Participants Who Entered the Study From Part II | Total |
|---|---|---|---|
| Japan | 21 | 23 | 44 |
The record gives a start of Apr 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →